Artiva Biotherapeutics (ARTV) Competitors $2.83 -0.17 (-5.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.82 -0.02 (-0.53%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. GLUE, RNAC, FHTX, RCKT, INBX, ABEO, AVIR, ALT, ALLO, and ADCTShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Abeona Therapeutics (ABEO), Atea Pharmaceuticals (AVIR), Altimmune (ALT), Allogene Therapeutics (ALLO), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Monte Rosa Therapeutics Cartesian Therapeutics Foghorn Therapeutics Rocket Pharmaceuticals Inhibrx Biosciences Abeona Therapeutics Atea Pharmaceuticals Altimmune Allogene Therapeutics ADC Therapeutics Monte Rosa Therapeutics (NASDAQ:GLUE) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Does the media favor GLUE or ARTV? In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 2 mentions for Artiva Biotherapeutics and 0 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 equaled Artiva Biotherapeutics'average media sentiment score. Company Overall Sentiment Monte Rosa Therapeutics Neutral Artiva Biotherapeutics Neutral Which has stronger earnings & valuation, GLUE or ARTV? Artiva Biotherapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M3.90-$72.70M$0.0859.88Artiva Biotherapeutics$250K275.76-$65.37MN/AN/A Is GLUE or ARTV more profitable? Monte Rosa Therapeutics has a net margin of 3.86% compared to Artiva Biotherapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 2.65% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics3.86% 2.65% 1.65% Artiva Biotherapeutics N/A -75.95%-39.51% Do analysts prefer GLUE or ARTV? Monte Rosa Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 220.11%. Artiva Biotherapeutics has a consensus target price of $17.80, indicating a potential upside of 528.98%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in GLUE or ARTV? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.9% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryArtiva Biotherapeutics beats Monte Rosa Therapeutics on 7 of the 12 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.09M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.6228.7823.81Price / Sales275.76179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.378.508.275.54Net Income-$65.37M-$55.06M$3.25B$259.28M7 Day Performance-21.39%-3.99%-3.70%-4.64%1 Month Performance77.99%9.58%4.34%4.41%1 Year Performance-75.79%6.70%25.90%17.95% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics2.1345 of 5 stars$2.83-5.7%$17.80+529.0%-75.6%$73.09M$250K0.0081News CoverageUpcoming EarningsGLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.55-2.1%$15.33+176.3%+9.6%$348.76M$75.62M69.3890RNACCartesian Therapeutics1.4107 of 5 stars$13.70+2.8%$40.00+192.0%-20.3%$345.97M$38.91M-0.2664Upcoming EarningsFHTXFoghorn Therapeutics2.4956 of 5 stars$6.50+5.0%$12.13+86.5%-23.3%$345.04M$22.60M-4.78120Upcoming EarningsGap DownRCKTRocket Pharmaceuticals4.8355 of 5 stars$3.11-1.0%$17.87+474.5%-86.5%$335.31MN/A-1.18240Trending NewsUpcoming EarningsINBXInhibrx Biosciences1.3548 of 5 stars$24.57+6.5%N/A+48.2%$334.11M$200K0.21166ABEOAbeona Therapeutics3.8538 of 5 stars$6.62+1.4%$19.25+190.8%+34.9%$334.05M$3.50M-5.2190News CoverageAVIRAtea Pharmaceuticals1.692 of 5 stars$3.79-2.8%$6.00+58.3%-4.4%$333.76MN/A-2.3070News CoverageUpcoming EarningsALTAltimmune2.2452 of 5 stars$4.03-1.2%$18.20+351.6%-40.7%$330.92M$20K-3.2050Upcoming EarningsALLOAllogene Therapeutics2.9872 of 5 stars$1.47-2.0%$8.44+474.5%-60.6%$328.10MN/A-1.20310News CoverageUpcoming EarningsADCTADC Therapeutics1.4092 of 5 stars$3.13-4.7%$7.75+148.0%-11.4%$325.30M$70.84M-2.16310News CoverageUpcoming Earnings Related Companies and Tools Related Companies GLUE Alternatives RNAC Alternatives FHTX Alternatives RCKT Alternatives INBX Alternatives ABEO Alternatives AVIR Alternatives ALT Alternatives ALLO Alternatives ADCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTV Stock Alerts